Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
EQRX

EQRx, Inc.

EQRX

2.34USD Market Closed
Watchlist

Market Summary

USD2.34
Market Closed

EQRX Alerts

  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

EQRX Stock Price

View Fullscreen

EQRX RSI Chart

EQRX Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-4.36

Price/Sales (Trailing)

18.71

Price/Free Cashflow

-3.42

EQRX Price/Sales (Trailing)

EQRX Profitability

Return on Equity

-20.72%

Return on Assets

-19.68%

Free Cashflow Yield

-29.23%

EQRX Fundamentals

EQRX Revenue

Revenue (TTM)

60.7M

Revenue Y/Y

100.82%

Revenue Q/Q

2.6%

EQRX Earnings

Earnings (TTM)

-260.3M

Earnings Y/Y

2.89%

Earnings Q/Q

-13.26%

Price Action

Last 7 days

9.6%

Last 30 days

7.7%

Last 90 days

7.7%

Trailing 12 Months

-56.0%

How does EQRX drawdown profile look like?

EQRX Financial Health

Current Ratio

22.63

EQRX Investor Care

Shares Dilution (1Y)

1.78%

Diluted EPS (TTM)

-0.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202340.4M52.4M60.7M0
20226.6M12.8M19.0M25.1M
2021181.8K266.5K351.3K436.0K
202000097.0K

Latest Insider Trading transactions for EQRX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 09, 2023
ah equity partners bio ii, l.l.c.
sold
-
-
-5,000,000
-
Nov 09, 2023
borisy alexis
back to issuer
-
-
-18,810,000
executive chairman
Nov 09, 2023
abernethy amy
back to issuer
-
-
-200,000
-
Nov 09, 2023
horning sandra
back to issuer
-
-
-470,250
-
Nov 09, 2023
conde jorge
back to issuer
-
-
-11,433,700
-
Nov 09, 2023
conde jorge
back to issuer
-
-
-5,000,000
-
Nov 09, 2023
conde jorge
back to issuer
-
-
-17,438,500
-
Nov 09, 2023
conde jorge
back to issuer
-
-
-19,192,000
-
Nov 09, 2023
nallicheri melanie
back to issuer
-
-
-3,851,150
chief executive officer
Nov 09, 2023
nallicheri melanie
acquired
1,385,670
2.21
626,999
chief executive officer

1–10 of 45

Which funds bought or sold EQRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
reduced
-26.11
-67,232
502,029
-%
Nov 24, 2023
DEUTSCHE BANK AG\
added
26.05
268,065
799,402
-%
Nov 22, 2023
Graham Capital Management, L.P.
sold off
-100
-41,491
-
-%
Nov 21, 2023
Alpine Global Management, LLC
new
-
3,332,430
3,332,430
0.42%
Nov 21, 2023
Walleye Capital LLC
added
58.12
-53,322
32,233
-%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
sold off
-100
-5,189,930
-
-%
Nov 15, 2023
MORGAN STANLEY
reduced
-34.81
-3,079,550
10,796,500
-%
Nov 15, 2023
SMITH, MOORE & CO.
unchanged
-
12,600
77,700
0.01%
Nov 15, 2023
MANUFACTURERS LIFE INSURANCE COMPANY, THE
reduced
-4.94
34,488
290,796
-%
Nov 15, 2023
GTS SECURITIES LLC
new
-
48,869
48,869
-%

1–10 of 46

Latest Funds Activity

Are funds buying EQRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EQRX
No. of Funds

Schedule 13G FIlings of EQRx, Inc.

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Nov 17, 2023
ah bio fund ii, l.p.
0.0%
0
SC 13D/A
Nov 17, 2023
arch venture fund x, l.p.
-
0
SC 13G/A
Nov 15, 2023
andreessen horowitz fund i, l.p.
0.0%
0
SC 13D/A
Nov 15, 2023
casdin capital, llc
0%
0
SC 13D/A
Feb 09, 2023
vanguard group inc
5.31%
25,952,741
SC 13G
Jan 18, 2023
softbank group corp
4.5%
21,800,000
SC 13D/A
Nov 29, 2022
casdin capital, llc
11.5%
56,297,042
SC 13D/A
Feb 14, 2022
gv 2019, l.p.
9.69%
47,252,687
SC 13G
Feb 14, 2022
citadel advisors llc
0.0%
6
SC 13G/A
Feb 11, 2022
arch venture fund x, l.p.
7.5%
36,335,375
SC 13G

Recent SEC filings of EQRx, Inc.

View All Filings
Date Filed Form Type Document
Nov 20, 2023
15-12G
15-12G
Nov 17, 2023
EFFECT
EFFECT
Nov 17, 2023
EFFECT
EFFECT
Nov 17, 2023
EFFECT
EFFECT
Nov 17, 2023
SC 13D/A
13D - Major Acquisition
Nov 17, 2023
SC 13G/A
Major Ownership Report
Nov 15, 2023
SC 13D/A
13D - Major Acquisition
Nov 15, 2023
SC 13D/A
13D - Major Acquisition
Nov 14, 2023
4
Insider Trading
Nov 09, 2023
4
Insider Trading

Peers (Alternatives to EQRx, Inc.)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
31.5B
-
5.25% 401813.88%
-3.7K
218.4K
- -102.45%
30.6B
10.7B
8.54% -55.34%
-8.83
2.87
-53.67% -129.46%
21.3B
1.7B
4.15% -23.37%
-41.84
12.38
79.37% 56.87%
17.5B
2.3B
11.05% -8.44%
119.09
7.58
15.05% 75.21%
12.3B
3.6B
0.84% -34.33%
28.84
3.4
8.35% -51.49%
MID-CAP
7.6B
272.9M
35.37% 34.74%
-12.51
27.78
141.38% 4.43%
5.9B
-
14.36% 263.35%
-10.02
48.33
54.84% -12.96%
3.6B
631.9M
-7.32% 48.57%
-24.01
5.65
23.54% 31.53%
3.3B
223.4M
11.28% -10.13%
-16.47
14.87
- -26.24%
2.6B
240.7M
-10.83% -25.35%
-12.82
10.93
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
11.36% -14.92%
24.33
4.33
81.69% -7.29%
661.3M
1.0B
-22.00% -67.89%
-1.2
0.63
-43.15% 58.48%
100.5M
6.4M
- -79.23%
-0.61
15.6
-44.11% 50.48%
37.6M
-
376.67% 112.17%
-0.58
-
- -29.23%
23.7M
-
25.24% 3980.68%
-0.5
-
- -13.74%

EQRx, Inc. News

Latest updates
Marketscreener.com08 Dec 202309:11 pm3 hours ago
Defense World30 Nov 202309:08 am8 days ago
Yahoo Finance09 Nov 202308:00 am29 days ago
Marketscreener.com06 Nov 202308:00 am32 days ago
Yahoo Finance06 Nov 202308:00 am32 days ago
Yahoo Finance01 Nov 202307:00 am37 days ago
Penny Stocks17 Oct 202307:00 am52 days ago
Marketscreener.com13 Oct 202307:00 am56 days ago
The Business Journals04 Oct 202307:00 am2 months ago
Yahoo Finance17 Aug 202307:00 am3 months ago
BP Journal03 Aug 202307:00 am4 months ago
Penny Stocks02 Aug 202307:00 am4 months ago
Yahoo Finance01 Aug 202307:00 am4 months ago
The Business Journals01 Aug 202307:00 am4 months ago

Financials for EQRx, Inc.

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue2.6%16,485,00016,068,00015,442,00012,668,0008,209,0004,091,000182,000127,66773,33319,000144,000-
Operating Expenses10.6%101,548,00091,836,000101,798,000100,730,00090,366,00079,090,00085,691,00094,801,00039,976,00034,639,00026,959,000-
  S&GA Expenses9.0%23,404,00021,476,00027,277,00029,232,00034,095,00031,792,00032,263,00038,585,00016,176,00013,223,00010,282,000-
  R&D Expenses-54.7%19,729,00043,574,00070,933,00071,498,00056,271,00047,298,00053,428,00056,216,00023,800,00021,416,00016,677,000-
EBITDA Margin-------226-226-226----
EBT Margin-------229-229-229----
Net Income-13.3%-82,631,000-72,956,000-82,551,000-22,177,000-85,092,000-82,546,00020,726,0001,233,000-39,890,000-34,526,000-26,817,000-
Net Income Margin----6.74-6.72-11.47-11.49-181-229-187-387--
Free Cashflow----85,990,000-106,753,000-62,118,000-65,579,000-53,951,000-182,835,674-447,36623,008,040--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12021Q12020Q4
Assets-5.4%1,2401,3111,3841,4551,5431,6081,6741,729554553536518501
  Current Assets-3.8%1,2351,2841,3551,4281,5241,5881,6551,7062.001.000.00-492
    Cash Equivalents27.8%3162483684949988641,6231,679456500537-490
  Net PPE-100.0%-2.003.003.002.002.002.002.00----3.00
Liabilities10.0%69.0063.0070.0066.0014313412621574.0081.00-39.0018.00
  Current Liabilities15.8%66.0057.0060.0052.0063.0055.0057.0040.002.000.000.000.0014.00
Shareholder's Equity-6.2%1,1711,2481,3141,3891,4001,4751,5491,5154564945270.00482
  Retained Earnings-12.1%-765-683-610-527-505-420-337-358-72.17-31.8448.00-751*-258
  Additional Paid-In Capital0.3%1,9361,9311,9241,9171,9071,8971,8861,873-37.000.000.00741
Shares Outstanding0.4%485483481479476473471469321318311-298
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Cashflow From Operations19.5%-61,907-76,891-85,546-105,796-62,104-65,430-53,938-80,384-41,966-37,309-23,521-
  Share Based Compensation-28.3%4,8696,7907,5929,2259,4329,98812,90622,4102,0161,016784-
Cashflow From Investing394.9%129,874-44,041-40,359-398,417194,916-693,763-13.00-4,104-49.00-252-43.00-
Cashflow From Financing182.4%20974.00127327774361-1,3231,306,560-1,67334571,256-

EQRX Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 19,729$ 56,271$ 134,236$ 156,997
General and administrative23,40434,09572,15798,150
Restructuring58,415 88,789 
Total operating expenses101,54890,366295,182255,147
Loss from operations(101,548)(90,366)(295,182)(255,147)
Other income (expense):    
Change in fair value of contingent earn-out liability(110)(2,706)4,55690,863
Change in fair value of warrant liabilities2,530(197)4,5014,934
Interest income, net16,4858,20947,99512,482
Other expense, net12(32)(8)(44)
Total other income (expense), net18,9175,27457,044108,235
Net loss(82,631)(85,092)(238,138)(146,912)
Other comprehensive income (loss), net of tax:    
Foreign currency translation adjustments(14)33(3)49
Unrealized holding gains (losses) on short-term investments132370403(1,672)
Comprehensive loss, net of tax(82,513)(84,689)(237,738)(148,535)
Net loss attributable to common stockholders - basic(82,631)(85,092)(238,138)(146,912)
Net loss attributable to common stockholders - diluted$ (82,631)$ (85,092)$ (238,138)$ (146,912)
Net income (loss) per share - basic (in dollars per share)$ (0.17)$ (0.18)$ (0.49)$ (0.31)
Net income (loss) per share - diluted (in dollars per share)$ (0.17)$ (0.18)$ (0.49)$ (0.31)
Weighted average common shares outstanding - basic (in shares)484,229,709475,565,990482,135,388473,101,935
Weighted average common shares outstanding - diluted (in shares)484,229,709475,565,990482,135,388473,101,935

EQRX Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 315,676$ 494,136
Short-term investments896,624905,150
Prepaid expenses and other current assets22,20628,800
Restricted cash633 
Total current assets1,235,1391,428,086
Property and equipment, net 2,627
Restricted cash 633
Right-of-use asset 3,804
Other investments4,0004,000
Other non-current assets1,15115,866
Total assets1,240,2901,455,016
Current liabilities:  
Accounts payable8,10319,950
Accrued expenses55,62329,596
Lease liability, current2,0602,370
Total current liabilities65,78651,916
Non-current liabilities:  
Contingent earn-out liability2,6047,160
Warrant liabilities7925,293
Lease liability, non-current 1,461
Restricted stock repurchase liability188324
Total liabilities69,37066,154
Commitments and contingencies (note 13)
Stockholders' equity:  
Preferred stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding as of September 30, 2023 and December 31, 2022
Common stock, $0.0001 par value; 1,250,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 537,540,870 and 538,549,210 shares issued as of September 30, 2023 and December 31, 2022, respectively; and 484,965,823 and 478,674,305 shares outstanding at September 30, 2023 and December 31, 2022, respectively4949
Additional paid-in capital1,936,3461,916,550
Accumulated other comprehensive income (loss)252(148)
Accumulated deficit(765,727)(527,589)
Total stockholders' equity1,170,9201,388,862
Total liabilities and stockholders' equity$ 1,240,290$ 1,455,016
EQRX
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.eqrx.com
 EMPLOYEES362

EQRx, Inc. Frequently Asked Questions


What is the ticker symbol for EQRx, Inc.? What does EQRX stand for in stocks?

EQRX is the stock ticker symbol of EQRx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of EQRx, Inc. (EQRX)?

As of Thu Nov 09 2023, market cap of EQRx, Inc. is 1.13 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EQRX stock?

You can check EQRX's fair value in chart. The fair value of EQRx, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of EQRx, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EQRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is EQRx, Inc. a good stock to buy?

The fair value guage provides a quick view whether EQRX is over valued or under valued. Whether EQRx, Inc. is cheap or expensive depends on the assumptions which impact EQRx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EQRX.

What is EQRx, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Nov 09 2023, EQRX's PE ratio (Price to Earnings) is -4.36 and Price to Sales (PS) ratio is 18.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EQRX PE ratio will change depending on the future growth rate expectations of investors.